Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study on voretigene neparvovec (Luxturna) in RPE65-associated inherited retinal degeneration
2021-000265-33Phase 4Active
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Jan 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of voretigene neparvovec in Fundus dystrophy, sponsored by Het Oogziekenhuis Rotterdam. Primary endpoint: Full-field stimulus test (FST). Started Jan 2021; status: active.
02
Drugs
voretigene neparvovec
03
Conditions
Fundus dystrophy
Beyond the preview
Go deeper on 2021-000265-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000265-33.